Cyclizine: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 22, 2026

Cyclizine

Piperazine Derivatives

GB MHRA

Drug class: Piperazine Derivatives
Availability: See label
Markets covered: 1
Products on record: 17

R06AEPiperazine Derivatives

Overview

Cyclizine is an active pharmaceutical ingredient in the Piperazine Derivatives group (R06AE). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	17	May 22, 2026

GBUnited Kingdom· MHRA

17 products

Uses

GBOfficial regulatory label· revised May 22, 2026[1]

Cyclizine lactate is indicated in adults for the prevention and treatment of nausea and vomiting including:- • Motion sickness when the oral route cannot be used. • Nausea and vomiting caused by narcotic analgesics and by general anaesthetics in the post-operative period.
• Vomiting associated with radiotherapy especially for breast cancer since Cyclizine does not elevate prolactin levels. • Cyclizine lactate injection, by the intravenous route, is also indicated pre- operatively in patients undergoing emergency surgery inorder to reduce the hazard of regurgitation and aspiration of gastric contents during induction of general anaesthesia.
Cyclizine lactate may be of value in relieving vomiting and attacks of vertigo associated with Menière's disease and other forms of vestibular disturbance when the oral route cannot be used.

Drug interactions

Known interactions involving Cyclizine. Select one for details. This list is informational and not a complete interaction checker.

Potassium Chloride Potassium Citrate Propoxyphene Topiramate Zonisamide Acetylcholine Aclidinium Acrivastine Aldesleukin Alfentanil Amantadine Amitriptyline Amobarbital Amoxapine Apomorphine Apraclonidine Aripiprazole Asenapine Atropine Azelastine Baclofen Benzhydrocodone Bethanechol Biperiden Botulinum Toxin Type A Botulinum Toxin Type B Brexanolone Brexpiprazole Brimonidine Brivaracetam Bromocriptine Brompheniramine Buprenorphine Buspirone Butorphanol Cannabidiol Carbamazepine Carbamoylcholine Carbinoxamine Cariprazine Carisoprodol Cenobamate Cetirizine Cevimeline Chlordiazepoxide Chlorpheniramine Chlorpromazine Chlorzoxazone Citalopram Clemastine Clidinium Clobazam Clomipramine Clonidine Clorazepate Clozapine Codeine Cyclobenzaprine Cyproheptadine Dantrolene Darifenacin Desipramine Desvenlafaxine Deutetrabenazine Dexbrompheniramine Dexmedetomidine Dextromethorphan Dicyclomine Dihydrocodeine Dimenhydrinate Diphenhydramine Disopyramide Donepezil Doxepin Doxylamine Dronabinol Droperidol Duloxetine Eluxadoline Entacapone Esketamine Eslicarbazepine Estazolam Eszopiclone Ethanol Ethotoin Ezogabine Fentanyl Fesoterodine Flavoxate Flibanserin Fluoxetine Fluphenazine Flurazepam Fosphenytoin Galantamine Glycopyrronium Haloperidol Homatropine Hydrocodone Hydromorphone Hydroxyzine Hyoscyamine Ifosfamide Iloperidone Imipramine Ipratropium Isocarboxazid Ketamine Lasmiditan Lemborexant Levocetirizine Levorphanol Linezolid Lithium Carbonate Lofexidine Loperamide Loxapine Lumateperone Lurasidone Maprotiline Meclizine Memantine Mepenzolate Meperidine Mephenytoin Mesoridazine Metaxalone Methadone Methocarbamol Methscopolamine Metoclopramide Metyrosine Mirtazapine Molindone Morphine Nabilone Nalbuphine Nefazodone Nortriptyline Olanzapine Oliceridine Olopatadine Opicapone Opium Orphenadrine Oxcarbazepine Oxybutynin Oxycodone Oxymorphone Paliperidone Paroxetine Pentazocine Pentobarbital Perampanel Pergolide Perphenazine Phenelzine Phenobarbital Phenyltoloxamine Phenytoin Physostigmine Pilocarpine Pimozide Pramipexole Pregabalin Primidone Procarbazine Prochlorperazine Procyclidine Promethazine Propantheline Protriptyline Prucalopride Pyrilamine Quazepam Quetiapine Ramelteon Rasagiline Remifentanil Revefenacin Risperidone Rivastigmine Ropinirole Rotigotine Rufinamide Scopolamine Secobarbital Sibutramine Solifenacin Stiripentol Sufentanil Suvorexant Tapentadol Tasimelteon Temazepam Tetrabenazine Thalidomide Thioridazine Thiothixene Tiagabine Timolol Tiotropium Tizanidine Tolcapone Tolterodine Tramadol Tranylcypromine Trazodone Triazolam Trifluoperazine Trihexyphenidyl Trimethobenzamide Trimipramine Triprolidine Trospium Umeclidinium Valbenazine Valproate Vigabatrin Zaleplon Ziconotide Ziprasidone Zolpidem Nitroglycerin Ranolazine

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL252980314 · revised May 22, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised May 22, 2026[1]

Adverse reactions are ranked under heading of frequency, the most frequent first, using the following convention: Very common: (≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1,000 to <1/100); Rare (≥1/10,000 to <1/1,000); Very rare(<1/10,000); Not known: cannot be estimated from the available data.
The following undesirable effects have been reported with a frequency of Not known. System Organ Class Frequency Adverse Reactions Blood and lymphatic system disorders Not known Agranulocytosis, leucopenia, haemolytic anaemia, thrombocytopenia.
4) Ear and labyrinth disorders Not known Tinnitus. There have been rare case reports of patients experiencing depressed levels of consciousness/loss of consciousness. Eye disorders Not known Blurred vision, oculogyric crisis Gastrointestinal system disorders Not known Dryness of the mouth, nose and throat, constipation, increased gastric reflux, nausea, vomiting, diarrhoea, stomach pain, loss of appetite.
General disorders and administration site conditions Not known Asthenia Injection site reactions including vein tracking, erythema, pain, thrombophlebitis and blisters. A sensation of heaviness, chills and System Organ Class Frequency Adverse Reactions pruritus have been reported rarely.
Anaphylaxis has been recorded following intravenous administration of cyclizine co- administered with propanidid in the same syringe. 4), hypersensitivity hepatitis, cholestatic jaundice and cholestatic hepatitis have occurred in association with cyclizine.
Immune system disorders Not known Hypersensitivity reactions, including anaphylaxis have occurred. Musculoskeletal and connective tissue disorders Not known Twitching, muscle spasms Nervous system disorders Not known Effects on the central nervous system have been reported with cyclizine these include somnolence, drowsiness, incoordination, headache, dystonia, dyskinesia, extrapyramidal motor disturbances, restless legs syndrome, tremor, convulsions, dizziness, decreased consciousness, transient speech disorders, paraesthesia, paralysis* and generalised chorea.
Psychiatric disorders Not known Disorientation, restlessness or agitation, nervousness, euphoria, insomnia and auditory and visual hallucinations have been reported, particularly when dosage recommendations have been exceeded. Renal and urinary disorders Not known Urinary retention Respiratory, thoracic and mediastinal disorders Not known Bronchospasm, apnoea Skin and subcutaneous tissue disorders Not known Urticaria, pruritus, drug rash, angioedema, allergic skin reactions, fixed drug eruption, photosensitivity Vascular disorders Not known Hypertension, hypotension * Case reports of paralysis have been received in patients using intravenous cyclizine.
4). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised May 22, 2026[1]

As with other anticholinergic agents, cyclizine lactate may precipitate incipient glaucoma and it should be used with caution and appropriate monitoring in patients with glaucoma, urinary retention, obstructive disease of the gastrointestinal tract, hepatic disease, pheochromocytoma, hypertension, epilepsy and in males with possible prostatic hypertrophy.
Cyclizine lactate injection may have a hypotensive effect. Cyclizine should be used with caution in patients with severe heart failure or acute myocardial infarction. In such patients, cyclizine may cause a fall in cardiac output associated with increases in heart rate, mean arterial pressure and pulmonary wedge pressure.
Cyclizine should be avoided in porphyria. There have been reports of abuse of cyclizine, either oral or intravenous, for its euphoric or hallucinatory effects. 5). Case reports of paralysis have been received in patients using intravenous cyclizine.
Some of the patients mentioned in these case reports had an underlying neuromuscular disorder. Thus intravenous cyclizine should be used with caution in all patients and with particular care in patients with underlying neuromuscular disorders.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drug interactions

Drugs in the same class

Sources & citations